Shares surge as clinical laboratory company exceeds expectations
- NeoGenomics stock rises 10% on earnings beat
- Company reports fourth-quarter loss of $14.33 million
- Adjusted earnings of 3 cents a share
- Fourth-quarter revenue increases to $155.55 million
- NeoGenomics issues upbeat guidance for full year
Shares of NeoGenomics surged 10% after the clinical laboratory company reported better-than-expected earnings for the fourth quarter. The company reported a loss of $14.33 million, or 11 cents a share, compared to a loss of $22.69 million, or 18 cents a share, in the same period last year. Adjusted earnings came in at 3 cents a share, beating analysts’ expectations of a 2 cent loss. Fourth-quarter revenue also exceeded expectations, reaching $155.55 million. NeoGenomics issued upbeat guidance for the full year, expecting a loss between $72 million and $66 million on revenues of $650 million to $660 million. Analysts predict a loss of $73.5 million on $647 million in revenue for the year.
Factuality Level: 9
Factuality Justification: The article provides factual information about NeoGenomics’ financial performance in the fourth quarter, including details on revenue, earnings, and analyst expectations. The information is presented in a straightforward manner without any obvious bias or sensationalism.
Noise Level: 3
Noise Justification: The article provides relevant information about NeoGenomics exceeding Wall Street expectations in the fourth quarter, including details about their financial performance, stock price movement, and analyst expectations. However, the article lacks in-depth analysis, accountability, antifragility, and actionable insights. It stays on topic and supports its claims with data, but it mainly focuses on financial figures without delving into broader implications or long-term trends.
Financial Relevance: Yes
Financial Markets Impacted: Shares of NeoGenomics
Presence Of Extreme Event: No
Nature Of Extreme Event: No
Impact Rating Of The Extreme Event: No
Rating Justification: The article pertains to financial topics as it discusses the financial performance and stock movement of NeoGenomics. There is no mention of any extreme event.
Public Companies: NeoGenomics (NEO)
Key People: Emon Reiser (Author)
Reported publicly:
www.marketwatch.com 
